The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women
Open accessAbstract
To assess whether androgen excess per se might impair insulin action, insulin sensitivity was measured by a two-step (20 and 80 mU/m2.min) hyperinsulinemic euglycemic clamp combined with indirect calorimetry and tracer glucose infusion in 43 women (13 obese and 30 nonobese) with normal glucose tolerance and clinical evidence of increased androgen action (hirsutism and/or polycystic ovary syndrome) as well as 12 age- and body mass index-matched healthy controls. Hyperandrogenic women were studied basally and after 3-4 months of antiandrogen treatment with 3 different drugs: spironolactone (n = 23), flutamide (n = 10), or the GnRH agonist buserelin (n = 10). Six women given spironolactone were also reexamined after 1 yr of therapy. At baseline, insulin-mediated glucose uptake was lower in hyperandrogenic women than in controls (by ANOVA, F = 14.3; P < 0.001). Insulin resistance was observed in both ovarian and nonovarian hyperandrogenism, as distinguished by acute GnRH agonist testing. After antiandrogen therapy, insulin action on glucose metabolism significantly increased for both the patients as a whole (F = 7.4; P < 0.01) and each treatment group separately. However, insulin action remained lower than in controls and showed no further improvement in patients reevaluated after I yr of treatment. Increases in both oxidative and nonoxidative glucose metabolism accounted for the improvement in substrate disposal induced by antiandrogen drugs. The increase in the effectiveness of insulin was greater in the lean subjects, whereas the change was small and not statistically significant in the obese women. Response to treatment was more pronounced in women with nonovarian hyperandrogenism, particularly at the low insulin infusion rate. Endogenous glucose production in hyperandrogenic patients was similar to that in healthy women and was unaffected by therapy. In conclusion, antiandrogen treatment partially reversed the peripheral insulin resistance associated with hyperandrogenism regardless of which antiandrogen was used. These data strongly suggest that in women, androgen excess per se contributes to impairment of insulin action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
NESTLER, J. E., BARLASCINI, C. O., CLORE, J. N., & BLACKARD, W. G. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-66-1-57 · Cited by 414
NESTLER, J. E., BARLASCINI, C. O., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., CLORE, J. N., & BLACKARD, W. G. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-6-1027 · Cited by 338
Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
Ciaraldi, T. P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.577 · Cited by 336
The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women
MORTOLA, J. F., & YEN, S. S. C. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-3-696 · Cited by 311
Testosterone concentrations in women and men with NIDDM
Andersson, B., Märin, P., Lissner, L., Vermeulen, A., & Björntorp, P. (1994) · Diabetes Care · doi:10.2337/diacare.17.5.405 · Cited by 268
Selective insulin action on skin, ovary, and heart in insulin-resistant states
Geffner, M. E., & Golde, D. W. (1988) · Diabetes Care · doi:10.2337/diacare.11.6.500 · Cited by 97
Cited by
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Gender differences in insulin resistance, body composition, and energy balance
Geer, E. B., & Shen, W. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.02.002 · Cited by 913
Obesity and the polycystic ovary syndrome
Gambineri, A., Pelusi, C., Vicennati, V, Pagotto, U., & Pasquali, R. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801994 · Cited by 836
The Insulin-Related Ovarian Regulatory System in Health and Disease
Poretsky, L., Cataldo, N. A., Rosenwaks, Z., & Giudice, L. C. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0374 · Cited by 818
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Self-citationAndrogens and Coronary Artery Disease
Wu, F. C. W., & von Eckardstein, A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0025 · Cited by 592
Obesity and reproductive disorders in women
Pasquali, R. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg024 · Cited by 539
Premature Adrenarche—Normal Variant or Forerunner of Adult Disease?*
Ibáñez, L., DiMartino-Nardi, J., Potau, N., & Saenger, P. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0416 · Cited by 416
Mannerås-Holm, L., Leonhardt, H., Kullberg, J., Jennische, E., Odén, A., Holm, G., Hellström, M., Lönn, L., Olivecrona, G., Stener-Victorin, E., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1290 · Cited by 369
Diamanti-Kandarakis, E., Kouli, C., Tsianateli, T., & Bergiele, A. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380269 · Cited by 323
Barrea, L., Arnone, A., Annunziata, G., Muscogiuri, G., Laudisio, D., Salzano, C., Pugliese, G., Colao, A., & Savastano, S. (2019) · Nutrients · doi:10.3390/nu11102278 · Cited by 306
“IR and the compensatory hyperinsulinemia might empower the androgenic activity, while the high levels of androgens may further blunt IR through alterations of the body composition [8], which results in a vicious circle that leads to a general worsening of this pathological status.”
BackgroundPolycystic ovary syndrome: Syndrome XX?
Sam, S., & Dunaif, A. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2003.08.002 · Cited by 302
Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294
“148 Moghetti, P. et al. (1996) The insulin resistance in”
BackgroundThe pathophysiology of polycystic ovary syndrome
Tsilchorozidou, T., Overton, C., & Conway, G. S. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01842.x · Cited by 294
Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome
Moghetti, P., Tosi, F., Bonin, C., Di Sarra, D., Fiers, T., Kaufman, J.-M., Giagulli, V. A., Signori, C., Zambotti, F., Dall'Alda, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3908 · Cited by 262
Self-citationGambineri, A., Patton, L., Vaccina, A., Cacciari, M., Morselli-Labate, A. M., Cavazza, C., Pagotto, U., & Pasquali, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2250 · Cited by 221
Dumesic, D. A., Akopians, A. L., Madrigal, V. K., Ramirez, E., Margolis, D. J., Sarma, M. K., Thomas, A. M., Grogan, T. R., Haykal, R., Schooler, T. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2586 · Cited by 222
Insulin resistance and PCOS: chicken or egg?
Moghetti, P., & Tosi, F. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01351-0 · Cited by 209
“However, interestingly, this alteration improved, at least in part, after different treatments aimed at reducing either androgen levels or androgen action, which supports an effect of hyperandrogenism on insulin sensitivity [84].”
BackgroundSelf-citationUnderstanding androgen action in adipose tissue
O’Reilly, M. W., House, P. J., & Tomlinson., J. W. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.04.008 · Cited by 180
Kalyani, R. R., Franco, M., Dobs, A. S., Ouyang, P., Vaidya, D., Bertoni, A., Gapstur, S. M., & Golden, S. H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0910 · Cited by 179
Tosi, F., Bonora, E., & Moghetti, P. (2017) · Human Reproduction · doi:10.1093/humrep/dex308 · Cited by 163
Self-citationMoghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200006000-00019 · Cited by 158
Self-citationAndrogen Excess in Pancreatic β Cells and Neurons Predisposes Female Mice to Type 2 Diabetes
Navarro, G., Allard, C., Morford, J. J., Xu, W., Liu, S., Molinas, A. J. R., Butcher, S. M., Fine, N. H. F., Blandino-Rosano, M., Sure, V. N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98607 · Cited by 80
Tosi, F., Di Sarra, D., Kaufman, J.-M., Bonin, C., Moretta, R., Bonora, E., Zanolin, E., & Moghetti, P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2786 · Cited by 70
Self-citationTolino, A., Gambardella, V., Caccavale, C., D’Ettore, A., Giannotti, F., D’Antò, V., & De Falco, C. L. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2004.06.043 · Cited by 69
Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
Herman, R., Sikonja, J., Jensterle, M., Janez, A., & Dolzan, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043140 · Cited by 69
“supraphysiological androgen administration in women [38,39], and that IR can be partially reversed by androgen suppression or antiandrogen treatment [40,41].”
BackgroundAllemand, M. C., Irving, B. A., Asmann, Y. W., Klaus, K. A., Tatpati, L., Coddington, C. C., & Nair, K. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004274 · Cited by 65
Holte, J. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03350784 · Cited by 52
Lu, C., Cardoso, R. C., Puttabyatappa, M., & Padmanabhan, V. (2016) · Biology of Reproduction · doi:10.1095/biolreprod.115.136283 · Cited by 40
Bacchi, E., Negri, C., Di Sarra, D., Tosi, F., Tarperi, C., Moretta, R., Schena, F., Bonora, E., Kaufman, J., & Moghetti, P. (2015) · Clinical Endocrinology · doi:10.1111/cen.12855 · Cited by 10
Self-citation
Metadata
- Authors
- Moghetti, P.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1996-03-01
- Volume
- 81
- Issue
- 3
- Pages
- 952-960
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W1999093110
- Cited by
- 245
- References
- 10
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.